Sorilux FDA Approval History
FDA Approved: Yes (First approved October 7, 2010)
Brand name: Sorilux
Generic name: calcipotriene
Dosage form: Foam
Company: Mayne Pharma US
Treatment for: Psoriasis
Sorilux (calcipotriene) is a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients 12 years and older.
Development timeline for Sorilux
| Date | Article |
|---|---|
| May 22, 2019 | Approval FDA Approves Sorilux for Adolescent Plaque Psoriasis |
| Oct 12, 2010 | Approval Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005% |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
